{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:45:59Z","timestamp":1789501559768,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yili Shen","award":["2023GY15;"],"award-info":[{"award-number":["2023GY15;"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03569-7","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:46:25Z","timestamp":1771238785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["GLP-1RAs: antidiabetic drug crossover\u2014new hope for chronic inflammatory airway diseases"],"prefix":"10.1186","volume":"27","author":[{"given":"Yinan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"3569_CR1","doi-asserted-by":"publisher","first-page":"1541559","DOI":"10.3389\/fnut.2025.1541559","volume":"12","author":"Z Luo","year":"2025","unstructured":"Luo Z, Chen S, Chen P, Qiu F, Huang W, Cao C. Oxidative balance score and its association with chronic inflammatory airway diseases and mortality: a population-based study. Front Nutr. 2025;12:1541559.","journal-title":"Front Nutr"},{"issue":"3","key":"3569_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.anai.2022.05.005","volume":"129","author":"A Mendy","year":"2022","unstructured":"Mendy A, Mersha TB. Comorbidities in childhood-onset and adult-onset asthma. Ann Allergy Asthma Immunol. 2022;129(3):327\u201334.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3569_CR3","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","volume":"59","author":"Global burden of chronic respiratory diseases and risk factors","year":"2023","unstructured":"Global burden of chronic respiratory diseases and risk factors. 1990\u20132019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine. 2023;59:101936.","journal-title":"EClinicalMedicine"},{"key":"3569_CR4","doi-asserted-by":"publisher","first-page":"111999","DOI":"10.1016\/j.diabres.2025.111999","volume":"222","author":"Z Wen","year":"2025","unstructured":"Wen Z, Sun W, Wang H, Chang R, Wang J, Song C, et al. Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight\/obesity: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2025;222:111999.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"3569_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12933-025-02608-9","volume":"24","author":"F Westermeier","year":"2025","unstructured":"Westermeier F, Fisman EZ. Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges. Cardiovasc Diabetol. 2025;24(1):44.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3569_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13098-025-01581-3","volume":"17","author":"X Miao","year":"2025","unstructured":"Miao X, Davoudi M, Alitotonchi Z, Ahmadi ES, Amraee F, Alemi A, et al. Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists. Diabetol Metab Syndr. 2025;17(1):13.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"3569_CR7","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.diabet.2024.101594","volume":"51","author":"AJ Scheen","year":"2025","unstructured":"Scheen AJ. Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies. Diabetes Metab. 2025;51(1):101594.","journal-title":"Diabetes Metab"},{"issue":"1","key":"3569_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12890-017-0443-1","volume":"17","author":"F De Santi","year":"2017","unstructured":"De Santi F, Zoppini G, Locatelli F, Finocchio E, Cappa V, Dauriz M, et al. Type 2 diabetes is associated with an increased prevalence of respiratory symptoms as compared to the general population. BMC Pulm Med. 2017;17(1):101.","journal-title":"BMC Pulm Med"},{"key":"3569_CR9","doi-asserted-by":"publisher","unstructured":"Jani\u0107 M, \u0160krgat S, Harlander M, Lunder M, Jane\u017e A, Pantea Stoian A. Potential Use of GLP-1 and GIP\/GLP-1 receptor agonists for respiratory disorders: where are we at? Medicina (Kaunas). 2024;60(12):2030. https:\/\/doi.org\/10.3390\/medicina60122030. PMID:39768911; PMCID: PMC11728110.","DOI":"10.3390\/medicina60122030"},{"key":"3569_CR10","doi-asserted-by":"publisher","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222370.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"3569_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fendo.2018.00672","volume":"9","author":"J Rowlands","year":"2018","unstructured":"Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne). 2018;9:672.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3569_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev. 2021;42(2):101\u201332.","journal-title":"Endocr Rev"},{"issue":"6","key":"3569_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","volume":"392","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. Discovery of GLP-1-based drugs for the treatment of obesity. N Engl J Med. 2025;392(6):612\u20135.","journal-title":"N Engl J Med"},{"issue":"1","key":"3569_CR14","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1192\/j.eurpsy.2024.1803","volume":"68","author":"W Lu","year":"2025","unstructured":"Lu W, Wang S, Tang H, Yuan T, Zuo W, Liu Y. Neuropsychiatric adverse events associated with glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA adverse event reporting system database. Eur Psychiatry. 2025;68(1):e20.","journal-title":"Eur Psychiatry"},{"issue":"11","key":"3569_CR15","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388.","journal-title":"Diabetes Care"},{"issue":"9","key":"3569_CR16","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1111\/dom.16581","volume":"27","author":"W Fu","year":"2025","unstructured":"Fu W, Lin J, You C, Zhang J, Lei J, Zheng L, et al. Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China. Diabetes Obes Metab. 2025;27(9):5280\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3569_CR17","doi-asserted-by":"publisher","first-page":"103186","DOI":"10.1016\/j.dsx.2025.103186","volume":"19","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhou Q, Onzere LE, Dian Y, Meng Y, Li D, et al. Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases. Diabetes Metab Syndr. 2025;19(1):103186.","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"3569_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951\u201362.","journal-title":"Nat Med"},{"issue":"1","key":"3569_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","volume":"24","author":"D Hullon","year":"2025","unstructured":"Hullon D, Subeh GK, Volkova Y, Janiec K, Trach A, Mnevets R. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF). Cardiovasc Diabetol. 2025;24(1):70.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"3569_CR20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1165\/rcmb.2015-0311OC","volume":"55","author":"P Rogliani","year":"2016","unstructured":"Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016;55(6):804\u201314.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10","key":"3569_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/1744666X.2021.1971973","volume":"17","author":"AY Wu","year":"2021","unstructured":"Wu AY, Peebles RS. The GLP-1 receptor in airway inflammation in asthma: a promising novel target? Expert Rev Clin Immunol. 2021;17(10):1053\u20137.","journal-title":"Expert Rev Clin Immunol"},{"key":"3569_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/COPD.S393323","volume":"18","author":"W Wang","year":"2023","unstructured":"Wang W, Mei A, Qian H, Li D, Xu H, Chen J, et al. The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2023;18:129\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"18","key":"3569_CR23","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3390\/cancers13184661","volume":"13","author":"MJ Batty","year":"2021","unstructured":"Batty MJ, Chabrier G, Sheridan A, Gage MC. Metabolic hormones modulate macrophage inflammatory responses. Cancers (Basel). 2021;13(18):4661.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"3569_CR24","doi-asserted-by":"publisher","first-page":"e5826","DOI":"10.1590\/1414-431x20165826","volume":"49","author":"C Guo","year":"2016","unstructured":"Guo C, Huang T, Chen A, Chen X, Wang L, Shen F, et al. Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. Braz J Med Biol Res. 2016;49(12):e5826.","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"3569_CR25","doi-asserted-by":"publisher","first-page":"18091","DOI":"10.1038\/s41598-020-74912-1","volume":"10","author":"J Fandi\u00f1o","year":"2020","unstructured":"Fandi\u00f1o J, Toba L, Gonz\u00e1lez-Mat\u00edas LC, Diz-Chaves Y, Mallo F. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci Rep. 2020;10(1):18091.","journal-title":"Sci Rep"},{"issue":"1","key":"3569_CR26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1186\/s12967-024-05753-z","volume":"22","author":"C Liu","year":"2024","unstructured":"Liu C, Zhang Q, Zhou H, Jin L, Liu C, Yang M, et al. GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome\/PFKFB3-driven glycolysis interaction and histone lactylation. J Transl Med. 2024;22(1):954.","journal-title":"J Transl Med"},{"issue":"5","key":"3569_CR27","first-page":"341","volume":"11","author":"PJ Barnes","year":"2022","unstructured":"Barnes PJ. Oxidative stress in chronic obstructive pulmonary disease. Antioxidants (Basel). 2022;11(5):341\u201357.","journal-title":"Antioxidants (Basel)"},{"key":"3569_CR28","doi-asserted-by":"publisher","first-page":"101544","DOI":"10.1016\/j.redox.2020.101544","volume":"33","author":"PJ Barnes","year":"2020","unstructured":"Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020;33:101544.","journal-title":"Redox Biol"},{"issue":"3","key":"3569_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.29271\/jcpsp.2019.03.218","volume":"29","author":"X Liu","year":"2019","unstructured":"Liu X, Huang J, Li J, Mao Q, He J. Effects of liraglutide combined with insulin on oxidative stress and serum MCP-1 and NF-kB levels in type 2 diabetes. J Coll Physicians Surg Pak. 2019;29(3):218\u201321.","journal-title":"J Coll Physicians Surg Pak"},{"key":"3569_CR30","doi-asserted-by":"publisher","first-page":"697440","DOI":"10.3389\/fnmol.2021.697440","volume":"14","author":"TK Lin","year":"2021","unstructured":"Lin TK, Lin KJ, Lin HY, Lin KL, Lan MY, Wang PW, et al. Glucagon-like peptide-1 receptor agonist ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity through enhancing mitophagy flux and reducing \u03b1-synuclein and oxidative stress. Front Mol Neurosci. 2021;14:697440.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"3569_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1210\/endocr\/bqaa201","volume":"161","author":"T Sato","year":"2020","unstructured":"Sato T, Shimizu T, Fujita H, Imai Y, Drucker DJ, Seino Y, et al. GLP-1 receptor signaling differentially modifies the outcomes of sterile vs viral pulmonary inflammation in male mice. Endocrinology. 2020;161(12):201.","journal-title":"Endocrinology"},{"issue":"3","key":"3569_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/jamaoto.2024.4593","volume":"151","author":"RCT Cheong","year":"2025","unstructured":"Cheong RCT, Pang KP. Neoadjuvant GLP-1 receptor agonists in sleep surgery. JAMA Otolaryngol Head Neck Surg. 2025;151(3):186\u20138.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"3569_CR33","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1038\/s41440-024-01852-y","volume":"47","author":"K Shiina","year":"2024","unstructured":"Shiina K. Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy. Hypertens Res. 2024;47(11):3085\u201398.","journal-title":"Hypertens Res"},{"issue":"11","key":"3569_CR34","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.3390\/biomedicines12112503","volume":"12","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Sagris M, Patoulias D, Koufakis T, Theofilis P, Klisic A, et al. mitigating increased cardiovascular risk in patients with obstructive sleep apnea using GLP-1 receptor agonists and SGLT2 inhibitors: hype or hope? Biomedicines. 2024;12(11):2503.","journal-title":"Biomedicines"},{"issue":"1","key":"3569_CR35","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.1038\/s41598-024-84040-9","volume":"15","author":"H Yin","year":"2025","unstructured":"Yin H, Huang W, Yang B. Association between METS-IR index and obstructive sleep apnea: evidence from NHANES. Sci Rep. 2025;15(1):6654.","journal-title":"Sci Rep"},{"key":"3569_CR36","doi-asserted-by":"publisher","first-page":"101774","DOI":"10.1016\/j.smrv.2023.101774","volume":"69","author":"S Mashaqi","year":"2023","unstructured":"Mashaqi S, Rangan P, Saleh AA, Abraham I, Gozal D, Quan SF, et al. Biomarkers of gut barrier dysfunction in obstructive sleep apnea: A systematic review and meta-analysis. Sleep Med Rev. 2023;69:101774.","journal-title":"Sleep Med Rev"},{"key":"3569_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejim.2024.10.027","volume":"132","author":"L Romariz","year":"2025","unstructured":"Romariz L, Ara\u00fajo B, Barbosa LM, Jain R, Porto Silva Janovsky CC. GLP-1 receptor agonists for the treatment of obstructive sleep apnea and obesity. Eur J Intern Med. 2025;132:153\u20135.","journal-title":"Eur J Intern Med"},{"key":"3569_CR38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/eurheartj\/ehaf447","volume":"5","author":"A Azarbarzin","year":"2025","unstructured":"Azarbarzin A, Vena D, Esmaeili N, Wellman A, Pinilla L, Messineo L, et al. Cardiovascular benefit of continuous positive airway pressure according to high-risk obstructive sleep apnoea: a multi-trial analysis. Eur Heart J. 2025;5:447.","journal-title":"Eur Heart J"},{"issue":"4","key":"3569_CR39","doi-asserted-by":"publisher","first-page":"zsaf004","DOI":"10.1093\/sleep\/zsaf004","volume":"48","author":"LF Drager","year":"2025","unstructured":"Drager LF. A meta-analysis of glucagon-like peptide 1 receptor and dual agonists for the treatment of obstructive sleep apnea: end of the story or just the beginning? Sleep. 2025;48(4):zsaf004.","journal-title":"Sleep"},{"key":"3569_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.sleep.2025.02.010","volume":"129","author":"CS Kow","year":"2025","unstructured":"Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials. Sleep Med. 2025;129:40\u20134.","journal-title":"Sleep Med"},{"issue":"2","key":"3569_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000526808","volume":"16","author":"D Yaz\u0131c\u0131","year":"2023","unstructured":"Yaz\u0131c\u0131 D, Yap\u0131c\u0131 Eser H, K\u0131y\u0131c\u0131 S, Sancak S, Sezer H, Uygur M, et al. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. Obes Facts. 2023;16(2):149\u201363.","journal-title":"Obes Facts"},{"issue":"3","key":"3569_CR42","first-page":"281","volume":"47","author":"BN Zhou","year":"2024","unstructured":"Zhou BN, Liu X, Hu K. Research status of glucagon-like peptide-1 receptor agonists on obstructive sleep apnea. Zhonghua Jie He He Hu Xi Za Zhi. 2024;47(3):281\u20135.","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"7","key":"3569_CR43","doi-asserted-by":"publisher","first-page":"e038856","DOI":"10.1136\/bmjopen-2020-038856","volume":"10","author":"VS Sprung","year":"2020","unstructured":"Sprung VS, Kemp GJ, Wilding JP, Adams V, Murphy K, Burgess M, et al. Randomised, controlled multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoea (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). BMJ Open. 2020;10(7):e038856.","journal-title":"BMJ Open"},{"issue":"5","key":"3569_CR44","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","volume":"27","author":"W Jiang","year":"2023","unstructured":"Jiang W, Li W, Cheng J, Li W, Cheng F. Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath. 2023;27(5):1687\u201394.","journal-title":"Sleep Breath"},{"issue":"13","key":"3569_CR45","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"issue":"9","key":"3569_CR46","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/diseases12090224","volume":"12","author":"S Dragonieri","year":"2024","unstructured":"Dragonieri S, Portacci A, Quaranta VN, Carratu P, Lazar Z, Carpagnano GE, et al. Therapeutic potential of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea syndrome management: a narrative review. Diseases. 2024;12(9):224.","journal-title":"Diseases"},{"issue":"6","key":"3569_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/MCP.0000000000001208","volume":"31","author":"DA D'Annibale","year":"2025","unstructured":"D\u2019Annibale DA, Mimoto M, McCowen KC, Malhotra A. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea. Curr Opin Pulm Med. 2025;31(6):591\u20136.","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"3569_CR48","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"7","key":"3569_CR49","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.cmet.2021.05.002","volume":"33","author":"D Borgmann","year":"2021","unstructured":"Borgmann D, Ciglieri E, Biglari N, Brandt C, Cremer AL, Backes H, et al. Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism. Cell Metab. 2021;33(7):1466-1482.e7.","journal-title":"Cell Metab"},{"issue":"8","key":"3569_CR50","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.3390\/ijms26083897","volume":"26","author":"S Sayers","year":"2025","unstructured":"Sayers S, Wagner E. On the pleiotropic actions of glucagon-like peptide-1 in its regulation of homeostatic and hedonic feeding. Int J Mol Sci. 2025;26(8):3897.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3569_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12967-025-06116-y","volume":"23","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Patel J, Fan J, Wang X, Chen L, Li Y, et al. Integrated analysis reveals that EGR1 promotes epithelial IL33 production in T2 asthma. J Transl Med. 2025;23(1):203.","journal-title":"J Transl Med"},{"key":"3569_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/bs.apha.2023.04.003","volume":"98","author":"GM Walsh","year":"2023","unstructured":"Walsh GM. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment. Adv Pharmacol. 2023;98:31\u201354.","journal-title":"Adv Pharmacol"},{"issue":"8","key":"3569_CR53","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/all.15807","volume":"78","author":"YH Shin","year":"2023","unstructured":"Shin YH, Hwang J, Kwon R, Lee SW, Kim MS, Shin JI, et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Allergy. 2023;78(8):2232\u201354.","journal-title":"Allergy"},{"issue":"1","key":"3569_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/ACI.0000000000000797","volume":"22","author":"AY Wu","year":"2022","unstructured":"Wu AY, Cahill KN, Toki S, Peebles RS Jr. Evaluating the glucagon-like peptide-1 receptor in managing asthma. Curr Opin Allergy Clin Immunol. 2022;22(1):36\u201341.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"3569_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/biomedicines12010173","volume":"12","author":"S \u0160krgat","year":"2024","unstructured":"\u0160krgat S, Harlander M, Jani\u0107 M. Obesity and insulin resistance in asthma pathogenesis and clinical outcomes. Biomedicines. 2024;12(1):173.","journal-title":"Biomedicines"},{"issue":"10","key":"3569_CR56","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1164\/rccm.202406-1166SO","volume":"210","author":"MD Althoff","year":"2024","unstructured":"Althoff MD, Gaietto K, Holguin F, Forno E. Obesity-related asthma: a pathobiology-based overview of existing and emerging treatment approaches. Am J Respir Crit Care Med. 2024;210(10):1186\u2013200.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3569_CR57","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","volume":"203","author":"D Foer","year":"2021","unstructured":"Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2021;203(7):831\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"3569_CR58","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.jaip.2024.05.002","volume":"12","author":"Y Kimura","year":"2024","unstructured":"Kimura Y, Jo T, Inoue N, Suzukawa M, Hashimoto Y, Kumazawa R, et al. Association of Novel Antihyperglycemic Drugs Versus Metformin With a Decrease in Asthma Exacerbations. J Allergy Clin Immunol Pract. 2024;12(8):2035\u201344.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"3569_CR59","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1513\/AnnalsATS.202309-836OC","volume":"21","author":"T Wang","year":"2024","unstructured":"Wang T, Keil AP, Buse JB, Keet C, Kim S, Wyss R, et al. Glucagon-like peptide 1 receptor agonists and asthma exacerbations: which patients benefit most? Ann Am Thorac Soc. 2024;21(11):1496\u2013506.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"3569_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","volume":"185","author":"B Lee","year":"2025","unstructured":"Lee B, Man KKC, Wong E, Tan T, Sheikh A, Bloom CI. Antidiabetic medication and asthma attacks. JAMA Intern Med. 2025;185(1):16\u201325.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"3569_CR61","doi-asserted-by":"publisher","first-page":"20195","DOI":"10.3390\/ijms160920195","volume":"16","author":"T Zhu","year":"2015","unstructured":"Zhu T, Wu XL, Zhang W, Xiao M. Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-\u03baB (NF-\u03baB) signaling pathway in mice. Int J Mol Sci. 2015;16(9):20195\u2013211.","journal-title":"Int J Mol Sci"},{"key":"3569_CR62","doi-asserted-by":"publisher","first-page":"102003","DOI":"10.1016\/j.pupt.2021.102003","volume":"67","author":"J Hur","year":"2021","unstructured":"Hur J, Kang JY, Kim YK, Lee SY, Lee HY. Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model. Pulm Pharmacol Ther. 2021;67:102003.","journal-title":"Pulm Pharmacol Ther"},{"issue":"11","key":"3569_CR63","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1111\/all.14879","volume":"76","author":"S Toki","year":"2021","unstructured":"Toki S, Newcomb DC, Printz RL, Cahill KN, Boyd KL, Niswender KD, et al. Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice. Allergy. 2021;76(11):3433\u201345.","journal-title":"Allergy"},{"issue":"3","key":"3569_CR64","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cea.12860","volume":"47","author":"PD Mitchell","year":"2017","unstructured":"Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin Exp Allergy. 2017;47(3):331\u20138.","journal-title":"Clin Exp Allergy"},{"issue":"11","key":"3569_CR65","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.3390\/biomedicines13112610","volume":"13","author":"J Radzik-Zaj\u0105c","year":"2025","unstructured":"Radzik-Zaj\u0105c J. The role of GLP-1 analogues in the treatment of obesity-related asthma phenotype. Biomedicines. 2025;13(11):2610.","journal-title":"Biomedicines"},{"issue":"10","key":"3569_CR66","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1164\/rccm.202303-0491OC","volume":"208","author":"D Foer","year":"2023","unstructured":"Foer D, Strasser ZH, Cui J, Cahill KN, Boyce JA, Murphy SN, et al. Association of GLP-1 receptor agonists with chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes. Am J Respir Crit Care Med. 2023;208(10):1088\u2013100.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3569_CR67","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1164\/rccm.202011-4162LE","volume":"203","author":"D Watchorn","year":"2021","unstructured":"Watchorn D, O\u2019Shea D, Butler MW. Asthma exacerbations in individuals on glucagon-like peptide-1 receptor agonists for type 2 diabetes. Am J Respir Crit Care Med. 2021;203(7):923\u20134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"3569_CR68","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/biom14121648","volume":"14","author":"A Januskevicius","year":"2024","unstructured":"Januskevicius A, Vasyle E, Rimkunas A, Palacionyte J, Kalinauskaite-Zukauske V, Malakauskas K. Serum T2-high inflammation mediators in eosinophilic COPD. Biomolecules. 2024;14(12):1648.","journal-title":"Biomolecules"},{"issue":"6","key":"3569_CR69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17476348.2024.2375416","volume":"18","author":"DMG Halpin","year":"2024","unstructured":"Halpin DMG. Mortality of patients with COPD. Expert Rev Respir Med. 2024;18(6):381\u201395.","journal-title":"Expert Rev Respir Med"},{"issue":"11","key":"3569_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.59556\/japi.73.1203","volume":"73","author":"SS Samajdar","year":"2025","unstructured":"Samajdar SS, Chatterjee R, Pal J, Chatterjee N, Haldar I, Tiwaskar M. Expanding the diagnostic horizon in COPD: insights from GOLD 2025 on early detection and comprehensive assessment. J Assoc Physicians India. 2025;73(11):69\u201378.","journal-title":"J Assoc Physicians India"},{"key":"3569_CR71","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.2147\/COPD.S539307","volume":"20","author":"H Bian","year":"2025","unstructured":"Bian H, Qian H, Zhu S, Xue J, Qi L, Peng X, et al. Nomogram model for identifying the risk of coronary heart disease in patients with chronic obstructive pulmonary disease based on deep learning radiomics and clinical data: a multicenter study. Int J Chron Obstruct Pulmon Dis. 2025;20:3045\u201357.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10356","key":"3569_CR72","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","volume":"400","author":"D Stolz","year":"2022","unstructured":"Stolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921\u201372.","journal-title":"Lancet"},{"issue":"1","key":"3569_CR73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41533-019-0138-6","volume":"29","author":"A Gayle","year":"2019","unstructured":"Gayle A, Dickinson S, Poole C, Pang M, Fauconnot O, Quint JK. Incidence of type II diabetes in chronic obstructive pulmonary disease: a nested case-control study. NPJ Prim Care Respir Med. 2019;29(1):28.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"1","key":"3569_CR74","first-page":"100","volume":"45","author":"H Xu","year":"2025","unstructured":"Xu H, Weng L, Xue H. CXCL12 is a potential therapeutic target for type 2 diabetes mellitus complicated by chronic obstructive pulmonary disease. Nan Fang Yi Ke Da Xue Xue Bao. 2025;45(1):100\u20139.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"3569_CR75","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/COPD.S350133","volume":"17","author":"AD Altintas Dogan","year":"2022","unstructured":"Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg EM, Juhl CB. Respiratory effects of treatment with a glucagon-like peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2022;17:405\u201314.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3569_CR76","doi-asserted-by":"publisher","first-page":"e071380","DOI":"10.1136\/bmj-2022-071380","volume":"379","author":"R Pradhan","year":"2022","unstructured":"Pradhan R, Lu S, Yin H, Yu OHY, Ernst P, Suissa S, et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ. 2022;379:e071380.","journal-title":"BMJ"},{"issue":"11","key":"3569_CR77","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/thorax-2023-221040","volume":"79","author":"FS Yen","year":"2024","unstructured":"Yen FS, Hsu CC, Wei JC, Tsai FJ, Huang Y, Yu TS, et al. Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD. Thorax. 2024;79(11):1017\u201323.","journal-title":"Thorax"},{"issue":"4","key":"3569_CR78","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamainternmed.2024.7811","volume":"185","author":"A Ray","year":"2025","unstructured":"Ray A, Paik JM, Wexler DJ, Sreedhara SK, Bykov K, Feldman WB, et al. Glucose-lowering medications and risk of chronic obstructive pulmonary disease exacerbations in patients with type 2 diabetes. JAMA Intern Med. 2025;185(4):399\u2013410.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"3569_CR79","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00210-016-1277-8","volume":"389","author":"\u0141 Bu\u0142dak","year":"2016","unstructured":"Bu\u0142dak \u0141, Machnik G, Bu\u0142dak RJ, \u0141abuzek K, Bo\u0142dys A, Okopie\u0144 B. Exenatide and metformin express their anti-inflammatory effects on human monocytes\/macrophages by the attenuation of MAPKs and NF\u03baB signaling. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(10):1103\u201315.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"3569_CR80","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64(2):399\u2013408.","journal-title":"J Hepatol"},{"issue":"1","key":"3569_CR81","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.pharep.2017.10.003","volume":"70","author":"E Gallego-Colon","year":"2018","unstructured":"Gallego-Colon E, Klych-Ratuszny A, Kosowska A, Garczorz W, Aghdam MRF, Wozniak M, et al. Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway. Pharmacol Rep. 2018;70(1):178\u201383.","journal-title":"Pharmacol Rep"},{"issue":"4","key":"3569_CR82","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41385-020-0262-1","volume":"13","author":"W Choi","year":"2020","unstructured":"Choi W, Choe S, Lin J, Borchers MT, Kosmider B, Vassallo R, et al. Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPAR\u03b3-FOXA2-phosphatase signaling. Mucosal Immunol. 2020;13(4):637\u201351.","journal-title":"Mucosal Immunol"},{"issue":"1","key":"3569_CR83","doi-asserted-by":"publisher","first-page":"e23618","DOI":"10.1002\/jbt.23618","volume":"38","author":"L Xu","year":"2024","unstructured":"Xu L, Chen G, Zhang L, He A, Li Y. Lixisenatide ameliorated lipopolysaccharide (LPS)-induced expression of mucin and inflammation in bronchial epithelial cells. J Biochem Mol Toxicol. 2024;38(1):e23618.","journal-title":"J Biochem Mol Toxicol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03569-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03569-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03569-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:02:21Z","timestamp":1774436541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03569-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3569"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03569-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}